A 315677

Drug Profile

A 315677

Alternative Names: A-315677

Latest Information Update: 30 Jan 2013

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Class Antivirals
  • Mechanism of Action Neuraminidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Influenza virus infections

Most Recent Events

  • 18 Sep 2006 Discontinued - Preclinical for Influenza virus infections in USA (unspecified route)
  • 12 Feb 2002 New profile
  • 12 Feb 2002 Preclinical development for Influenza virus infections in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top